Multidisciplinary Approach to Prevent de novo Hepatitis B in Patients with Rheumatoid Arthritis.

In conclusion, our multidisciplinary approach to prevent de novo hepatitis B is considered useful. PMID: 33028756 [PubMed - in process]
Source: The Tohoku Journal of Experimental Medicine - Category: Research Authors: Tags: Tohoku J Exp Med Source Type: research

Related Links:

HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glob...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
AbstractObjectivesPrimary objective: to evaluate the efficacy of melatonin as a prophylactic treatment on prevention of symptomatic SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 exposure.Secondary objectives:To evaluate the efficacy of melatonin as a prophylactic treatment on prevention of asymptomatic SARS-CoV-2 infection.To evaluate the efficacy of melatonin to prevent the development of severe COVID-19 in the participants enrolled in this study who develop SARS-CoV-2 infection along the trial.To evaluate the duration of COVID-19 symptoms in participants receiving melatonin before the infection...
Source: Trials - Category: Research Source Type: clinical trials
Perhaps you’ve grown as weary as I have of repeated arthritis ads. They appear in frequent rotation on television, online, and in magazines, promoting Enbrel, Humira, Otezla, Xeljanz, and others. If you’ve actually read or listened to these ads, you might have felt perplexed at certain points. Here’s a quick rundown on what they’re saying — and not saying — in one of those ads. “The clock is ticking” Part 1: A teakettle whistles on the stove and a disembodied voice speaks as this ad for Humira opens. “This is your wakeup call. If you have moderate to severe rheumatoid a...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Arthritis Bones and joints Health Inflammation Source Type: blogs
Perhaps you’ve grown as weary as I have of repeated arthritis ads. They appear in frequent rotation on television, online, and in magazines, promoting Enbrel, Humira, Otezla, Xeljanz, and others. If you’ve actually read or listened to these ads, you might have felt perplexed at certain points. Here’s a quick rundown on what they’re saying — and not saying — in one of those ads. “The clock is ticking” Part 1: A teakettle whistles on the stove and a disembodied voice speaks as this ad for Humira opens. “This is your wakeup call. If you have moderate to severe rheumatoid a...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Arthritis Bones and joints Health Inflammation Source Type: blogs
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion ava...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
In patients who have resolved hepatitis B virus (HBV) infection, treatment of rheumatoid arthritis (RA) can result in reappearance of hepatitis B surface antigen (HBsAg), called reverse seroconversion. We investigated clinical features and outcomes of reverse seroconversion in patients who received immunosuppressant or biologic therapy for RA.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
ConclusionGiven the relatively low incidence of immune ‐related AEs and the comparability of clinical outcomes, ICIs can be treatment option of NSCLC patients with special issues.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
CONCLUSIONS An increased frequency of musculoskeletal manifestations, better than those reported in the medical literature, in patients infected with HBV and HCV was observed.
Source: Revista da Sociedade Brasileira de Medicina Tropical - Category: Tropical Medicine Source Type: research
The prophylaxis for hepatitis B virus (HBV) reactivation assumes that hepatic injury after reactivation is often rapidly progressive and can evoke fulminant hepatitis. The incidence and prognosis of reactivati...
Source: Arthritis Research and Therapy - Category: Rheumatology Authors: Tags: Research article Source Type: research
Conclusions Patients with RA receiving DMARDs had less humoral response to hepatitis B vaccination as compared with control subjects. Aging and rituximab use were associated with impaired response to hepatitis B vaccination. Hepatitis B vaccination is safe and well tolerated in RA patients.
Source: JCR: Journal of Clinical Rheumatology - Category: Rheumatology Tags: Original Articles Source Type: research
More News: Arthritis | Hepatitis | Hepatitis B | Japan Health | Liver | Methotrexate | Nurses | Nursing | Research | Rheumatoid Arthritis | Rheumatology | Science | Study | Urology & Nephrology